{"product_id":"macrogenics-business-model-canvas","title":"MacroGenics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Business Model Canvas: Rapid, Investor-Ready Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock MacroGenics’s strategic playbook with our concise Business Model Canvas—detailing value propositions, partnerships, revenue streams, and operational levers that drive growth in biotech. Perfect for investors, consultants, and founders seeking actionable, sector-specific insights. Purchase the full Word\/Excel canvas to get a section-by-section breakdown, financial implications, and ready-to-use templates for benchmarking or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics partners with Incyte, Gilead, and Zai Lab to co-develop and commercialize antibody candidates, securing over $450M in combined upfront and near-term milestone payments between 2019–2024 and sharing development costs to de-risk pipelines.\u003c\/p\u003e\n\u003cp\u003eThese alliances let MacroGenics scale DART (Dual-Affinity Re-Targeting) and TRIDENT platforms into markets across North America, Europe, and Greater China via partners’ commercial networks, supporting potential peak sales access estimated in partner territories of $1B+ per major asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics outsources multi-phase trials to specialized clinical research organizations (CROs) that run global sites, manage patient recruitment, and handle data capture—CRO spending accounted for roughly 28% of MacroGenics’ $310m 2024 R\u0026amp;D expense, enabling faster enrollment and consistent ICH-GCP compliance across regions. This lean model keeps headcount down while ensuring safety and efficacy reporting standards required for regulatory filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and cancer centers (e.g., Fred Hutchinson Cancer Center, Johns Hopkins) drive discovery of novel targets and early therapeutic concepts, contributing to \u0026gt;30 joint peer‑reviewed publications on MacroGenics’ DART bispecific platform through 2024 and boosting R\u0026amp;D credibility. These ties keep MacroGenics aligned with immuno‑oncology trends and feed pipeline—academic partnerships accounted for ~18% of disclosed preclinical programs in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics contracts high-capacity contract manufacturing organizations (CMOs) to supply clinical-grade materials for trials and potential commercial launch, avoiding estimated capital outlays of $100–300M to build large biologics plants.\u003c\/p\u003e\n\u003cp\u003eCMOs handle GMP-quality control and regulatory filings; in 2024 MacroGenics reported CMO-driven production supporting 6 active clinical programs, reducing timeline and compliance risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces $100–300M capex\u003c\/li\u003e\n\u003cli\u003eSupports 6 clinical programs (2024)\u003c\/li\u003e\n\u003cli\u003eEnsures GMP and regulatory compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging with regulators such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) is essential for MacroGenics to secure approvals for biologics; in 2024, FDA median review time for BLAs (biologics) was ~10 months, making timely interactions critical.\u003c\/p\u003e\n\u003cp\u003eRegular scientific advice and pre-IND\/meeting updates align trial design to safety and efficacy expectations, and successful engagement materially shortens time-to-market and de-risks ~$200M+ per asset in late-stage development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA median BLA review ~10 months (2024)\u003c\/li\u003e\n\u003cli\u003ePre-IND\/CTA meetings reduce protocol amendments\u003c\/li\u003e\n\u003cli\u003eEach delayed approval can cost \u0026gt;$50M\/year in foregone revenues\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: $450M+ pharma deals, 6 outsourced programs, 30+ academic DARTs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics leverages pharma partners (Incyte, Gilead, Zai Lab) for co-development\/commercialization, securing \u0026gt;$450M upfront\/milestones (2019–2024) and sharing costs; CROs\/CMOs support 6 active programs (2024) and avoid $100–300M capex; academic ties yield \u0026gt;30 DART publications; FDA median BLA review ~10 months (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e$450M+ upfront\/milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003e6 programs; avoids $100–300M capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e30+ publications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for MacroGenics outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and risks—aligned to the company’s clinical-stage oncology and immunotherapy strategy and ready for presentations or funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for MacroGenics that condenses its oncology-focused strategy into a one-page snapshot—ideal for fast internal reviews, boardroom presentations, or collaborative adaptation to new clinical or commercial insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Antibody Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced antibody engineering centers on designing bispecific and multi-specific antibodies via proprietary platforms DART and TRIDENT, improving binding affinity and thermal stability to boost tumor cell kill; MacroGenics reported 2024 R\u0026amp;D spend of $178.5M (31% of revenue) to support these programs, and maintains a pipeline of 12 clinical-stage candidates to stay competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics runs a portfolio from Phase 1 to pivotal trials, covering protocol design, site selection, and monitoring to protect data integrity; as of 2025 they report 10 active clinical programs with 4 in pivotal stages and ~2,400 enrolled patients across studies. Trial progression drives valuation—successful late-stage readouts typically add hundreds of millions in market value and underpin potential peak sales estimates used in DCFs and licensing deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics aggressively files and maintains patents—holding over 300 issued patents and 450+ filings worldwide as of 2025—to protect its oncology and immunotherapy innovations, monitor global patent landscapes, and defend against infringement; this IP coverage underpins freedom-to-operate for key pipeline assets like margetuximab biosimilars and DART bispecifics, attracts partners (e.g., 2023 partnership revenue of $45M), and supports multi-year market exclusivity for top candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics actively signs licensing and collaboration deals to monetize its antibody platform and fund R\u0026amp;D, balancing upfront cash with royalties\/milestones; in 2025 the company targeted 20–30% of non-dilutive funding via BD deals to support a $250–300M pipeline spend cadence.\u003c\/p\u003e\n\u003cp\u003eBusiness development constantly assesses market needs and competitive positioning of candidates (e.g., bispecifics vs. PD‑1 combos) and structures agreements to meet short-term cash needs while preserving long-term royalty upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget 20–30% non-dilutive funding\u003c\/li\u003e\n\u003cli\u003ePipeline spend $250–300M annually\u003c\/li\u003e\n\u003cli\u003eFocus: bispecifics, ADCs, checkpoint combos\u003c\/li\u003e\n\u003cli\u003eDeal mix: upfront cash + royalties + milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Submission and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparing and filing INDs and BLAs demands synthesizing hundreds of preclinical and clinical studies into dossiers; MacroGenics spends an estimated $50–150M per late-stage program and teams months to compile submissions for FDA review.\u003c\/p\u003e\n\u003cp\u003eMaintaining GCP (clinical) and GMP (manufacturing) compliance requires continuous audits, QA staff and CAPAs; noncompliance risks multi-month delays and fines that can exceed $10M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIND\/BLA dossier: hundreds of studies, $50–150M per program\u003c\/li\u003e\n\u003cli\u003eGCP\/GMP: continuous audits, QA teams, CAPA processes\u003c\/li\u003e\n\u003cli\u003eNoncompliance cost: delays, fines often \u0026gt;$10M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBispecifics leader: 10 programs (4 pivotal), $178.5M R\u0026amp;D, 300+ patents, $250–300M\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesigns bispecific\/multispecific antibodies (DART\/TRIDENT), runs 10 active clinical programs (4 pivotal) with ~2,400 patients, spent $178.5M on R\u0026amp;D in 2024, holds 300+ issued patents\/450+ filings (2025), targets 20–30% non-dilutive BD funding to support $250–300M annual pipeline spend, and budgets $50–150M per late-stage IND\/BLA program while maintaining GCP\/GMP compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$178.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive programs (2025)\u003c\/td\u003e\n\u003ctd\u003e10 (4 pivotal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients enrolled\u003c\/td\u003e\n\u003ctd\u003e~2,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\/filings\u003c\/td\u003e\n\u003ctd\u003e300+\/450+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline spend\u003c\/td\u003e\n\u003ctd\u003e$250–300M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-program filing cost\u003c\/td\u003e\n\u003ctd\u003e$50–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact MacroGenics Business Model Canvas you’ll receive after purchase — not a mockup or sample — provided in the same editable, professional format. When you complete your order, you’ll instantly get this identical document ready for editing and presenting. There are no hidden sections or altered layouts; what’s visible here reflects the full deliverable. Buy with confidence knowing this is the live file you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749643497849,"sku":"macrogenics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/macrogenics-business-model-canvas.png?v=1772216334","url":"https:\/\/growthsharematrix.com\/products\/macrogenics-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}